Literature DB >> 1602545

Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2.

E D Garrett1, B R Cullen.   

Abstract

The Rev proteins of the related but distinct human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) display incomplete functional reciprocity. One possible explanation for this observation is that HIV-2 Rev is unable to interact with the HIV-1 Rev-response element (RRE1). However, an analysis of the biological activity of chimeric proteins derived from HIV-1 and HIV-2 Rev reveals that this target specificity does not map to the Rev RNA binding domain but is instead primarily determined by sequences known to mediate Rev multimerization. Both HIV-1 and HIV-2 Rev are shown to bind the RRE1 in vitro with identical RNA sequence specificity. The observation that HIV-2 Rev can inhibit RRE1-dependent HIV-1 Rev function in trans indicates that the direct interaction of HIV-2 Rev with the RRE1 also occurs in vivo. These data suggest that HIV-2 Rev forms a protein-RNA complex with the RRE1 that leads to only minimal Rev activity. It is hypothesized that this low level of Rev function results from the incomplete and/or aberrant multimerization of HIV-2 Rev on this heterologous RNA target sequence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602545      PMCID: PMC241234     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif.

Authors:  M L Zapp; T J Hope; T G Parslow; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

2.  Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein.

Authors:  L S Tiley; M H Malim; H K Tewary; P G Stockley; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

3.  Extensive sequence-specific information throughout the CAR/RRE, the target sequence of the human immunodeficiency virus type 1 Rev protein.

Authors:  E T Dayton; D A Konings; D M Powell; B A Shapiro; L Butini; J V Maizel; A I Dayton
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

4.  Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev.

Authors:  J Kjems; A D Frankel; P A Sharp
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

5.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

6.  The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization.

Authors:  M Emerman; R Vazeux; K Peden
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

7.  Regulation of human immunodeficiency virus env expression by the rev gene product.

Authors:  M L Hammarskjöld; J Heimer; B Hammarskjöld; I Sangwan; L Albert; D Rekosh
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

9.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

10.  Compatibility of rev gene activity in the four groups of primate lentiviruses.

Authors:  H Sakai; R Shibata; J Sakuragi; T Kiyomasu; M Kawamura; M Hayami; A Ishimoto; A Adachi
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

View more
  11 in total

Review 1.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

2.  Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals.

Authors:  B E Meyer; J L Meinkoth; M H Malim
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 3.  A potentially novel approach for the gene therapy of HIV-1 disease.

Authors:  Z N Berneman
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

4.  Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

5.  Inhibition of HIV-1 expression by HIV-2.

Authors:  J Rappaport; S K Arya; M W Richardson; G Baier-Bitterlich; P E Klotman
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

6.  Identification of the activation domain of equine infectious anemia virus rev.

Authors:  R A Fridell; K M Partin; S Carpenter; B R Cullen
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex.

Authors:  K J Krohn; K Hakkarainen; E Aavik; S Dewhurst; R Sadaie; J I Mullins
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.

Authors:  J H Simon; T E Southerling; J C Peterson; B E Meyer; M H Malim
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.

Authors:  A K Iversen; E G Shpaer; A G Rodrigo; M S Hirsch; B D Walker; H W Sheppard; T C Merigan; J I Mullins
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  The HIV-2 Rev-response element: determining secondary structure and defining folding intermediates.

Authors:  Sabrina Lusvarghi; Joanna Sztuba-Solinska; Katarzyna J Purzycka; Gary T Pauly; Jason W Rausch; Stuart F J Le Grice
Journal:  Nucleic Acids Res       Date:  2013-05-02       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.